StoxWockhardt vs Neuland Laboratories: share price & financials comparison
NSE: WOCKPHARMA vs NEULANDLAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Wockhardt vs Neuland Laboratories at a glance
Wockhardt (WOCKPHARMA) has a market capitalisation of ₹32,841 Cr, against ₹27,192 Cr for Neuland Laboratories (NEULANDLAB). Over the past year Wockhardt has returned +48.5%, compared with +19.7% for Neuland Laboratories. On valuation, Neuland Laboratories trades at a lower P/E of 60.1 versus 80.1. Neuland Laboratories earns a higher return on equity (22.3% vs 7.9%). Neuland Laboratories comes out ahead on size, profitability, financial health, momentum and technicals. Across the scored metrics below, Wockhardt leads on 4 and Neuland Laboratories on 12. On StoxGud's 10-point checklist, Wockhardt scores 6/10 and Neuland Laboratories scores 6/10.
| Metric | Wockhardt | Neuland Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹32,841 Cr | ₹27,192 Cr |
| Revenue (latest FY) | ₹3,373 Cr | ₹2,023 Cr |
| Net profit (latest FY) | ₹213 Cr | ₹364 Cr |
| Valuation | ||
| P/E | 80.1 | 60.1 |
| P/B | 6.37 | 13.40 |
| Dividend yield | — | 0.06% |
| Profitability | ||
| Return on equity | 7.9% | 22.3% |
| Net profit margin | 10.9% | 19.6% |
| Operating margin | 20.4% | 30.6% |
| Growth | ||
| Revenue growth (YoY) | +23.9% | -12.6% |
| Net profit growth (YoY) | +1.3% | — |
| Revenue CAGR (multi-year) | +4.5% | +16.6% |
| Financial health | ||
| Debt to equity | 0.42 | 0.17 |
| Momentum | ||
| 1-month return | +2.2% | +3.5% |
| 1-year return | +48.5% | +19.7% |
| 3-year CAGR | +92.3% | +60.1% |
| 5-year CAGR | +36.5% | +66.4% |
| 10-year CAGR | +11.2% | +35.7% |
| Distance from 52W high | -13.0% | -12.2% |
| Technicals | ||
| RSI (14) | 74 | 74 |
| Price vs 200-day avg | +17.2% | +19.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Wockhardt | Neuland Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Wockhardt or Neuland Laboratories?
Wockhardt has a market cap of ₹32,841 Cr and Neuland Laboratories has a market cap of ₹27,192 Cr as of 13 Nov 2026.
Which has a lower P/E, Wockhardt or Neuland Laboratories?
Neuland Laboratories has the lower P/E: Wockhardt trades at 80.1 and Neuland Laboratories at 60.1.
Which gave better returns in the last year, Wockhardt or Neuland Laboratories?
Wockhardt did better: Wockhardt returned +48.5% and Neuland Laboratories returned +19.7% over one year.
What is the difference between Wockhardt and Neuland Laboratories?
Both are NSE-listed companies in Healthcare. Wockhardt is about 1.2 times the size of Neuland Laboratories by market cap. In the latest financial year Wockhardt reported revenue of ₹3,373 Cr and Neuland Laboratories ₹2,023 Cr. Operating margin is 20.4% for Wockhardt and 30.6% for Neuland Laboratories. Debt to equity is 0.42 for Wockhardt and 0.17 for Neuland Laboratories.
Which is better, Wockhardt or Neuland Laboratories?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Wockhardt leads on 4 and Neuland Laboratories on 12. Neuland Laboratories is ahead on size, profitability, financial health, momentum and technicals. On StoxGud's rules-based checklist Wockhardt scores 6/10 and Neuland Laboratories scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.